Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
BRF2 encodes one of the multiple subunits of the RNA polymerase III transcription factor complex required for transcription of genes with promoter elements upstream of the initiation site. Additionally we are shipping BRF2, Subunit of RNA Polymerase III Transcription Initiation Factor, BRF1-Like Proteins (9) and BRF2, Subunit of RNA Polymerase III Transcription Initiation Factor, BRF1-Like Kits (5) and many more products for this protein.
Showing 10 out of 45 products:
Cow (Bovine) Polyclonal BRF2 Primary Antibody for WB - ABIN2784260
Ewing, Chu, Elisma, Li, Taylor, Climie, McBroom-Cerajewski, Robinson, OConnor, Li, Taylor, Dharsee, Ho, Heilbut, Moore, Zhang, Ornatsky, Bukhman, Ethier, Sheng, Vasilescu, Abu-Farha, Lambert, Duewel et al.: Large-scale mapping of human protein-protein interactions by mass spectrometry. ... in 2007
Human Polyclonal BRF2 Primary Antibody for ELISA, WB - ABIN184848
Schramm, Pendergrast, Sun, Hernandez: Different human TFIIIB activities direct RNA polymerase III transcription from TATA-containing and TATA-less promoters. in Genes & development 2000
Study solved crystal structures of a human Brf2-TATA-binding complex bound to natural promoters, obtaining a detailed view of the molecular interactions occurring at Brf2-dependent Pol III promoters and highlighting the general structural and functional conservation of human Pol II and Pol III pre-initiation complexes.
hnRNP F (show HNRNPF Antibodies) is a co-factor in a subset of tristetraprolin (show ZFP36 Antibodies)/BRF1 (show ZFP36L1 Antibodies)/BRF2 (show ZFP36L2 Antibodies)-mediated mRNA decay.
These results suggested that BRF2 (show ZFP36L2 Antibodies) overexpression in tumor tissues is significantly associated with the poor prognosis of NSCLC patients through promoting epithelial-mesenchymal transition (EMT (show ITK Antibodies)) program.
BRF2 (show ZFP36L2 Antibodies) may have a role in poor prognosis and anti-angiogenic therapy for early-stage non-small cell lung cancer
High expression of BRF2 (show ZFP36L2 Antibodies) is closely associated with tumor progression, angiogenesis, and poor survival in esophageal squamous cell cancer.
BRF2 (show ZFP36L2 Antibodies) can serve as a marker for lung squamous cell carcinoma and may provide a novel target for therapy.
C-terminal domain of Brf2 (show ZFP36L2 Antibodies) is required for efficient association of the protein with U6 promoter-bound TBP (show TBP Antibodies) and SNAP(c), a type 3 promoter-specific transcription factor, and for efficient recruitment of Bdp1 (show PTPN18 Antibodies)
deregulation of Brf1 and Brf2 expression could be a key mechanism responsible for the observed deregulation of RNA pol III transcription in cancer cells
This gene encodes one of the multiple subunits of the RNA polymerase III transcription factor complex required for transcription of genes with promoter elements upstream of the initiation site. The product of this gene, a TFIIB-like factor, is directly recruited to the TATA-box of polymerase III small nuclear RNA gene promoters through its interaction with the TATA-binding protein.
BRF2, subunit of RNA polymerase III transcription initiation factor, BRF1-like
, RNA polymerase III transcription initiation factor BRF2
, zinc finger protein 36, C3H type-like 2
, transcription factor IIIB 50 kDa subunit-like
, B-related factor 2
, RNA polymerase III transcription initiation factor BRFU
, transcription factor IIB- related factor, TFIIIB50
, transcription factor IIIB 50 kDa subunit